Please login to the form below

Not currently logged in
Email:
Password:

Shire picks Bayer's Flemming Ornskov as new head

He will succeed Angus Russell who is retiring next year

Shire Flemming OrnskovAngus Russell is stepping down as chief executive of the Dublin-based specialty pharmaceutical company Shire next year.

His replacement will be Flemming Ornskov, who is currently chief marketing office and global head of strategic marketing (general and specialty medicine) at Bayer.

Ornskov will join the company on January 2, 2013, as chief executive designate, spend time with all three Shire businesses and will have a special focus initially on the specialty pharmaceuticals business.

He will be based at Shire's US offices outside Philadelphia, during this period, following after which he will become CEO on April 30, 2013.

Flemming Ornskov said: “Shire stands out in the industry. I'm motivated and inspired by the company's vision and excited to bring the combination of my medical, multi-national and entrepreneurial business background to lead Shire to the next phase of its development.”

Prior to his time at Bayer, Ornskov was global president, pharmaceuticals and OTC at Bausch & Lomb. Before this he served as CEO at both Lifecycle Pharma and US biotech Ikaria, and worked at Merck & Co and Novartis.

His selection as CEO came as part of Shire's search for a new president for its specialty pharmaceuticals business after the resignation in April of Michael Kola. A process the company intended to yield a potential successor for Angus Russell.

Russell will retire in 2013 after 13 years with Shire and a full 32 years of working in the pharmaceutical industry.

Shire chair Matthew Emmens said: “Angus led the company through a period of extraordinary growth and was instrumental in establishing a winning strategy and a powerful and compelling culture. We wish him and his family well in his retirement.”

26th October 2012

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics